UBS Group
BITI icon

UBS Group’s BIOTIE THERAPIES CORP SPONSORED ADR BITI Stock Holding History

UBS Group’s Portfolio BITI Stock Details BITI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,085
Closed -$16K – 8674
2015
Q4 		$16K Buy
+1,085
New +$15.2K ﹤0.01% 6980
2015
Q3 		– Sell
-681
Closed -$14K – 8919
2015
Q2 		$14K Buy
+681
New +$14.2K ﹤0.01% 7218

Other funds holding BITI

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.58% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return

UBS Group's BITI Position: Q1 2016 in Review

UBS Group sold out of BIOTIE THERAPIES CORP SPONSORED ADR (BITI) in Q1 2016, closing a stake of 1,085 shares — an estimated $16K sold.

UBS Group first reported a position in BITI in Q2 2015 and held it in 2 quarters. The position peaked at $16K in Q4 2015. 19 funds tracked by Wall St. Rank hold BITI as of Q1 2016.

  • UBS Group reported no remaining BIOTIE THERAPIES CORP SPONSORED ADR position as of Q1 2016 after selling out during the quarter.
  • UBS Group sold 1,085 BIOTIE THERAPIES CORP SPONSORED ADR shares in Q1 2016, an estimated $16K.
  • UBS Group first reported a position in BIOTIE THERAPIES CORP SPONSORED ADR in Q2 2015 and held it in 2 quarters.
  • UBS Group's BIOTIE THERAPIES CORP SPONSORED ADR position peaked at $16K in Q4 2015.
  • 19 funds tracked by Wall St. Rank held BIOTIE THERAPIES CORP SPONSORED ADR as of Q1 2016.

Based on UBS Group's 13F filing for Q1 2016, filed 12 May 2016.